Literature DB >> 2512690

Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease.

D L Bowton1, D A Stump, D S Prough, J F Toole, D S Lefkowitz, L Coker.   

Abstract

We determined the immediate effects of pentoxifylline on cerebral blood flow in 10 patients with cerebrovascular disease; four received 400 mg and six received 800 mg pentoxifylline orally. Regional cerebral blood flow was measured before (baseline) and 2, 4, and 6 hours after pentoxifylline administration using the xenon-133 clearance technique with 16 detectors (eight per hemisphere). Global cerebral blood flow as a percentage of the baseline value increased significantly after 800 mg but not 400 mg pentoxifylline (p = 0.017 and p = 0.29, respectively). Regional cerebral blood flow as a percentage of the baseline value at the detector with the lowest baseline value increased significantly 2 hours after both 400 mg and 800 mg pentoxifylline (p = 0.038 and p = 0.010, respectively). Cerebrovascular reactivity to carbon dioxide was preserved despite the increases in cerebral blood flow. Pentoxifylline increases cerebral blood flow and is not associated with "intracerebral steal" in patients with cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512690     DOI: 10.1161/01.str.20.12.1662

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Pentoxifylline attenuates ischemia/reperfusion injury to the small intestine in the rat.

Authors:  R Udassin; A Vromen; D Seror; Y Haskel
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

2.  Pentoxifylline reduces chronic post-ischaemia pain by alleviating microvascular dysfunction.

Authors:  J Vaigunda Ragavendran; A Laferrière; M Khorashadi; T J Coderre
Journal:  Eur J Pain       Date:  2013-07-31       Impact factor: 3.931

3.  Vancomycin Is Protective in a Neonatal Mouse Model of Staphylococcus epidermidis-Potentiated Hypoxic-Ischemic Brain Injury.

Authors:  Jacqueline C Y Lai; Pernilla Svedin; C Joakim Ek; Amin Mottahedin; Xiaoyang Wang; Ofer Levy; Andrew Currie; Tobias Strunk; Carina Mallard
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

Review 5.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 6.  Pentoxifylline for vascular health: a brief review of the literature.

Authors:  Mark F McCarty; James H O'Keefe; James J DiNicolantonio
Journal:  Open Heart       Date:  2016-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.